Synairgen plc (LON:SNG – Get Rating)'s stock price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 12.55 ($0.15) and traded as low as GBX 9 ($0.11). Synairgen shares last traded at GBX 9 ($0.11), with a volume of 897,679 shares changing hands.
Synairgen Stock Down 6.5 %
The company has a fifty day simple moving average of GBX 12.55 and a 200-day simple moving average of GBX 16.22. The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.09. The firm has a market cap of £18.12 million, a P/E ratio of -69.23 and a beta of -2.20.
Synairgen Company Profile
(Get Rating)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
See Also
- First Republic Bank Hits New Low, Dimon Pushes for More Cash
- Mullen Automotive: Investment? No. Compelling Speculation, Yes
- GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
- General Mills Retreats To Buy Zone Ahead Of Earnings
- Foot Locker: Slow And Steady Wins The Race
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
在周一的交易中,Synairgen plc(伦敦股票代码:SNG-GET Rating)的股价跌破了50日移动均线。该股的50日移动均线为12.55英镑(0.15美元),最低交易价格为9英镑(0.11美元)。Synairgen的股票最新交易价格为9英镑(0.11美元),成交量为897,679股。
Synairgen股价下跌6.5%
该公司的50日简单移动均线为12.55英镑,200天简单移动均线为16.22英镑。该公司的速动比率为6.35,流动比率为6.35,债务权益比为0.09。该公司的市值为1812万GB,市盈率为-69.23,贝塔系数为-2.20。
Synairgen公司简介
(获取评级)
Synairgen plc发现和开发治疗呼吸系统疾病的药物。该公司开发的产品有:治疗新冠肺炎的乙型吸入型干扰素SG001;治疗感冒和流感引起的哮喘的乙型干扰素吸入剂;治疗或预防慢性阻塞性肺病的乙型干扰素第二阶段临床试验;以及治疗特发性肺纤维化的LXL2抑制剂。
另请参阅
- First Republic Bank创新低,戴蒙推动更多现金
- 马伦汽车:投资?不是的。令人信服的猜测,是的
- GBTC:以58美分的面值购买比特币的唯一地方
- 通用磨坊在盈利之前撤退到购买区
- 脚锁:稳扎稳打赢得比赛
接受Synairgen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synairgen和相关公司的最新新闻和分析师评级的每日简明摘要。